Marché mondial du traitement du cancer du pancréas – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché

Ces dernières années, le marché du traitement du cancer du pancréas devrait connaître une croissance rapide au cours de la période de prévision. Le cancer du pancréas représente environ 3 % de tous les cancers aux États-Unis, selon l'American Cancer Society (ACS). L'American Cancer Society estime que 60 430 personnes ont reçu un diagnostic de cancer du pancréas en 2021. Le cancer du pancréas étant difficile à détecter, il n'est souvent découvert qu'après avoir atteint un stade avancé. La jaunisse et la perte de poids sont deux symptômes du cancer du pancréas. Le diabète et l'exposition à certaines toxines sont tous deux des facteurs de risque. Le type de traitement dépend de la taille et de l'emplacement de la tumeur et de sa propagation à d'autres parties du corps.

Français Data Bridge Market Research analyse que le marché du traitement du cancer du pancréas était évalué à 2 236,17 millions USD en 2021 et devrait atteindre 6 245,81 millions USD d'ici 2029, enregistrant un TCAC de 13,70 % au cours de la période de prévision de 2022 à 2029. Le rapport de marché organisé par l'équipe Data Bridge Market Research comprend une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Définition du marché

Le cancer du pancréas se développe lorsque des cellules se développent de manière incontrôlée dans une région du pancréas. La jaunisse et les douleurs abdominales sont des symptômes courants, mais ils peuvent ne se manifester que plus tard dans la progression de la maladie. Le pancréas se trouve à l'arrière du ventre, près de la vésicule biliaire, derrière l'estomac. Il est composé de glandes qui produisent des hormones et des enzymes, dont l'insuline. Le cancer du pancréas est rarement découvert à ses premiers stades, lorsqu'il est le plus facile à traiter. En effet, il ne manifeste souvent aucun symptôme avant d'avoir progressé vers d'autres organes. La gravité de la maladie détermine les choix de traitement pour le cancer du pancréas. La chirurgie, la chimiothérapie, la radiothérapie ou une combinaison de ces traitements sont toutes des options possibles.

Portée du rapport et segmentation du marché

Dynamique du marché du traitement du cancer du pancréas

Conducteurs

• Prévalence croissante du cancer

La prévalence croissante du cancer devrait favoriser la croissance du marché. La mutation du gène BRCA2, le syndrome de Lynch et le syndrome du mélanome malin atypique familial (FAMMM) sont des types d'anomalies génétiques qui pourraient augmenter le risque de cancer dans la famille. L'incidence croissante du diabète et de l'obésité augmentera le risque de cancer du pancréas, influençant ainsi la dynamique du marché.

• Augmenter les investissements dans les infrastructures de santé

Un autre facteur important qui influence le taux de croissance du marché du traitement du cancer du pancréas est l’augmentation des dépenses de santé, qui contribue à améliorer son infrastructure. En outre, diverses organisations gouvernementales visent à améliorer l’infrastructure des soins de santé en augmentant le financement, ce qui influencera davantage la dynamique du marché.

• Nombre croissant de personnes âgées

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to get pancreatic cancer treatment, further estimated to enhance the market's growth rate.

Furthermore, rising initiatives by public and private organizations to spread awareness and advancements in molecular biology will expand the pancreatic cancer treatment market. Additionally, increasing addiction to smoking and growing tobacco consumption will result in expanding the pancreatic cancer treatment market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the pancreatic cancer treatment market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate. 

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the pancreatic cancer treatment market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the pancreatic cancer treatment market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This pancreatic cancer treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pancreatic cancer treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

According to the American Cancer Society, pancreatic cancer accounts for about 3% of all malignancies and 7% of all cancer deaths in the United States. Men are slightly more likely than women to get the condition.

Pancreatic cancer treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Pancreatic Cancer Treatment Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in pneumonia cases. This virus spread quickly over the world, killing many people. COVID-19 was labeled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The supply chain slowness hampered the pancreatic cancer treatment market.

Recent Development

• In January 2022, U.S. Food and Drug Administration (FDA) had granted orphan drug designation to multitargeted T-cell therapy for the treatment of pancreatic cancer. MT-601 (Marker Therapeutics) is an autologous, nongene-edited T-cell treatment made up of cytotoxic T lymphocyte lines that attack cancer cells' surface proteins PRAME, SSX2, MAGEA4, NY-ESO-1, and Survivin.

Global Pancreatic Cancer Treatment Market Scope

The pancreatic cancer treatment market is segmented on the basis of treatment type, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Hormone Therapy
• Others

Diagnosis

• Blood Test
• Biopsy
• Imaging Tests
• Ultrasound
• Computerized tomography (CT) scans
• Magnetic resonance imaging (MRI)
• Positron emission tomography (PET) scans
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Pancreatic Cancer Treatment Market Regional Analysis/Insights

The pancreatic cancer treatment market is analysed and market size insights and trends are provided by country, treatment type, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the pancreatic cancer treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the pancreatic cancer treatment market because of the rising cases of pancreatic cancer in this region. Additionally, rising healthcare expenditure and favorable government policies will further propel the market's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to the increasing level of disposable income in this region. Also, the development of healthcare infrastructure and rising government initiatives will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Pancreatic Cancer Treatment Market Share Analysis

The Pancreatic cancer treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pancreatic cancer treatment market.

Some of the major players operating in the pancreatic cancer treatment market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• Zydus Cadila (India)
• AstraZeneca (UK)
• Johnson & Johnson (US)
• Bayer AG (Germany)
• Sun Pharmaceutical Industries Ltd. (India)
• Bristol-Myers Squibb Company (US)
• Eli Lilly and Company (US)
• Amgen Inc. (US)
• Achieve Life Sciences, Inc (US)
• Infinity Pharmaceuticals Inc. (US)
• Takeda Pharmaceutical Company Limited (Japan)
• Astellas Pharma Inc. (Japon)

SKU-54139